Evidence map›Paper›PMID 34122907›Full record

ArticleChemical science2020

Chemical synthesis and immunological evaluation of new generation multivalent anticancer vaccines based on a Tn antigen analogue.

Carlo Pifferi, Ane Ruiz-de-Angulo, David Goyard, Claire Tiertant, Nagore Sacristán, Diego Barriales, Nathalie Berthet, Juan Anguita, Olivier Renaudet, Alberto Fernández-Tejada

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Carlo PifferiDépartement de Chimie Moléculaire, Université Grenoble Alpes, UMR 5250, CNRS 38000 Grenoble France olivier.renaudet@ujf-grenoble.fr.ORCID https://orcid.org/0000-0003-0861-1378
Ane Ruiz-de-AnguloChemical Immunology Lab, CIC bioGUNE Biscay Science and Technology Park, Building 801A 48160 Derio Spain afernandeztejada@cicbiogune.es.ORCID https://orcid.org/0000-0001-6581-4038
David GoyardDépartement de Chimie Moléculaire, Université Grenoble Alpes, UMR 5250, CNRS 38000 Grenoble France olivier.renaudet@ujf-grenoble.fr.ORCID https://orcid.org/0000-0002-6410-0866
Claire TiertantDépartement de Chimie Moléculaire, Université Grenoble Alpes, UMR 5250, CNRS 38000 Grenoble France olivier.renaudet@ujf-grenoble.fr.
Nagore SacristánChemical Immunology Lab, CIC bioGUNE Biscay Science and Technology Park, Building 801A 48160 Derio Spain afernandeztejada@cicbiogune.es.
Diego BarrialesInflammation and Macrophage Plasticity Lab, CIC bioGUNE Biscay Science and Technology Park, Building 801A 48160 Derio Spain janguita@cicbiogune.es.ORCID https://orcid.org/0000-0002-6433-3379
Nathalie BerthetDépartement de Chimie Moléculaire, Université Grenoble Alpes, UMR 5250, CNRS 38000 Grenoble France olivier.renaudet@ujf-grenoble.fr.ORCID https://orcid.org/0000-0002-3479-1918
Juan AnguitaInflammation and Macrophage Plasticity Lab, CIC bioGUNE Biscay Science and Technology Park, Building 801A 48160 Derio Spain janguita@cicbiogune.es.ORCID https://orcid.org/0000-0003-2061-7182
Olivier RenaudetDépartement de Chimie Moléculaire, Université Grenoble Alpes, UMR 5250, CNRS 38000 Grenoble France olivier.renaudet@ujf-grenoble.fr.ORCID https://orcid.org/0000-0003-4963-3848
Alberto Fernández-TejadaChemical Immunology Lab, CIC bioGUNE Biscay Science and Technology Park, Building 801A 48160 Derio Spain afernandeztejada@cicbiogune.es.ORCID https://orcid.org/0000-0002-1680-0059
Département de Chimie Moléculaire · FRCIC bioGUNE · ESIkerbasque · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor associated carbohydrate antigens (TACAs), such as the Tn antigen, have emerged as key targets for the development of synthetic anticancer vaccines. However, the induction of potent and functional immune responses has been challenging and, in most cases, unsuccessful. Herein, we report the design, synthesis and immunological evaluation in mice of Tn-based vaccine candidates with multivalent presentation of the Tn antigen (up to 16 copies), both in its native serine-linked display (Tn-Ser) and as an oxime-linked Tn analogue (Tn-oxime). The high valent vaccine prototypes were synthesized through a late-stage convergent assembly (Tn-Ser construct) and a versatile divergent strategy (Tn-oxime analogue), using chemoselective click-type chemistry. The hexadecavalent Tn-oxime construct induced robust, Tn-specific humoral and CD4

Identifiers

PMID34122907
PMCPMC8159477
OpenAlexW3015567984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.